{
    "ACTIVITY": [],
    "CODE": [],
    "ENDPOINT": [],
    "INDICATION": [
        {
            "indication_desc": "Mild to Moderate Alzheimer\u0092s Disease",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/indic-1"
        }
    ],
    "INVESTIGATIONAL_INTERVENTIONS": [
        {
            "indication_desc": "Xanomeline",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/trt-1"
        }
    ],
    "OBJECTIVE": [
        {
            "objective_desc": "To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/obj-1"
        },
        {
            "objective_desc": "To document the safety profile of the xanomeline TTS.",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/obj-2"
        },
        {
            "objective_desc": "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/obj-3"
        },
        {
            "objective_desc": "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/obj-4"
        },
        {
            "objective_desc": "To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The ADAS-Cog (14) will be used for this assessment.",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/obj-5"
        },
        {
            "objective_desc": "To assess the treatment response as a function of Apo E genotype.",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/obj-6"
        }
    ],
    "POPULATION": [
        {
            "population_desc": "Not known",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/spop"
        }
    ],
    "PROCEDURE": [],
    "RULE": [],
    "STUDY": [
        {
            "key": "http://id.d4k.dk/dataset/study/cdisc/pilot",
            "study_status": "???",
            "study_tag": "???",
            "study_title": "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer\u0092s Disease.",
            "study_version": "???"
        }
    ],
    "STUDY_ARM": [],
    "STUDY_CELL": [],
    "STUDY_DATA": [],
    "STUDY_DESIGN": [
        {
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/sd"
        }
    ],
    "STUDY_ELEMENT": [],
    "STUDY_EPOCH": [],
    "STUDY_IDENTIFIER": [
        {
            "id_type": "SponsorID",
            "name": "Sponsor",
            "org_code": "CDISC Pilot",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/sident-1"
        }
    ],
    "STUDY_PHASE": [
        {
            "study_type_phase": "Phase II Trial",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/tphase-1"
        }
    ],
    "STUDY_PROTOCOL": [
        {
            "PublicTitle": "The Lilly CDISC Pilot",
            "amendments": "",
            "brief_title": "CDISC PILOT",
            "key": "http://id.d4k.dk/dataset/study/cdisc/pilot/spr",
            "official_title": "Targeting Agents in ABTC",
            "scientific_title": "Scientific Title"
        }
    ],
    "STUDY_TYPE": [
        {
            "study_type_classification": "SAFETY",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/ttype-1"
        },
        {
            "study_type_classification": "EFFICACY",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/ttype-2"
        },
        {
            "study_type_classification": "PHARMACOKINETIC",
            "uri": "http://id.d4k.dk/dataset/study/cdisc/pilot/ttype-3"
        }
    ],
    "VISIT": [],
    "WORKFLOW_ITEM": []
}